Δημοσίευση στις 2019/2/26 στο PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30799785
Dimitriadis K, Tsioufis C, Iliakis P, Kasiakogias A, Andrikou I, Leontsinis I, Konstantinidis D, Tousoulis D.
Targeting the renin-angiotensin-aldosterone axis is one of the most important therapeutic pathways for blood pressure control, renal and cardiovascular protection.
In this review the new nonsteroidal mineralcorticoid receptor antagonists will be presented with a special focus on finerenone and its randomized controlled trials along with an introduction to the clinically promising aldosterone synthase inhibitors. Methhod: We conducted an in-detail review of the literature in order to draft a narrative review on the field.
Development of new anti-aldosterone agents focusing on the diverse components of aldosterone production and action is emerging. Nonsteroidal mineralοcorticoid receptor antagonists are safe and effective therapeutic solutions with finerenone being the most well-studied agent with promising clinical data extending its efficacy in diabetes mellitus, chronic kidney disease and heart failure. Aldosterone synthase inhibitors impact the hormonal balance but there are still limitations regarding the duration of action and adverse effect of the glycol-corticoid axis.
Novel third-generation, nonsteroidal mineralocorticoid receptor antagonists seem to offer great advantages, which may lead to a wider use of mineralocorticoid receptor antagonists. Future randomized controlled trials are needed to evaluate significant perspectives.
Copyright© Bentham Science Publishers; For any queries, please email at email@example.com.